TO THE EDITOR
We read with great interest the article by Rajkumar et al 1 on the effects of thalidomide in early-stage asymptomatic multiple myeloma. The authors propose that thalidomide may act by suppressing an angiogenic switch, thereby preventing progression of disease.
Another possible effect by which thalidomide may be acting in the early-stage disease is by anti-inflammatory effect. There is much suggestive evidence that inflammation is involved in the progression of plasma cell dyscrasia in the animal model, and that anti-inflammatory agents such as aspirin and celecoxib can inhibit disease progression. 2, 3 In humans, multiple myeloma is often associated with high CRP, il-6, beta 2 microglobulin, hypercoagulability, 4 and response to steroids, all suggesting chronic ongoing inflammation.
Thalidomide has potent anti-inflammatory effects through inhibition of tumor necrosis factor, suppression of NF kappa B activation in response to inflammatory agents, and downregulation of cell adhesion molecules LFA-l and ICAM-l. 5, 6 We wonder if the investigators have information about the effects of thalidomide on inflammatory markers in their patients, and if changes in inflammation corresponded to tumor response.
If the actions of thalidomide are through anti-inflammatory mechanisms, then other anti-inflammatory agents could be considered as adjunctive or alternative agents to prevent progression of asymptomatic to symptomatic disease. Ongoing studies to determine if celecoxib can achieve such an effect through anti-inflammatory mechanisms are ongoing at the Cleveland Clinic, Mayo Clinic, and the University of Arkansas. 
Reply to Dr Mehta
Leukemia ( We agree with Dr Mehta that anti-inflammatory properties of thalidomide may play a role in its antimyeloma effect. 1 As mentioned in our report, 2 there are several hypothesized mechanisms of action postulated for thalidomide, including effects on tumor cell growth and apoptosis, angiogenesis, cytokines that mediate inflammation, the immune system, and adhesion molecules. The precise mechanism of action of thalidomide has been difficult to elucidate because of its relative lack of activity in in vitro assays compared to effects in vivo, and the fact that, in solutions at physiologic pH (including blood plasma), it undergoes spontaneous nonenzymatic hydrolysis into 12 or more metabolites. 3, 4 We have studied a variety of cytokines including TNFa and IL-6 in the context of thalidomide therapy. Our findings suggest that patients with higher pretreatment plasma levels of TNFa may have an inferior progression-free survival with thalidomide therapy (alone or in combination with dexamethasone) for newly diagnosed myeloma. 5 We also find that patients with an increase in plasma IL-6 levels post-therapy may have inferior progression-free survival compared to patients whose levels stay stable or decrease with therapy. In contrast, plasma levels of angiogenic cytokines VEGF and bFGF did not predict response to therapy or change significantly following therapy in our study. These results are preliminary, but support Dr Mehta's point that the mechanism of action of thalidomide in myeloma may include anti-inflammatory effects.
We also agree with Dr Mehta that there is a need to study the role of anti-inflammatory agents in the progression of myeloma. For instance, there are data that IL-1b, a key mediator of inflammation, is involved in the progression of asymptomatic myeloma to symptomatic disease. 6 A clinical trial using an IL-1 receptor antagonist to prevent the progression of early-stage myeloma is now ongoing at the Mayo Clinic. 
